News Releases

 
News Releases
  Date Title and Summary View
May 10, 2017
-- Phase III clinical trial of avacopan for the treatment of ANCA Vasculitis underway as Journal of American Society of Nephrology (JASN) publishes results of successful Phase II CLEAR clinical trial -- -- Received FDA Orphan Drug Designation for avacopan in the treatment of C3 Glomerulopathy (C3G) -- -- Conference call today at 5:00 p.m. Eas...
Apr 27, 2017
MOUNTAIN VIEW, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's first quarter 2017 financial results will be released after market close on Wednesday, May 10, 2017. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on Wednesday, May 10,...
Mar 22, 2017
MOUNTAIN VIEW, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for avacopan in the treatment of patie...
Mar 14, 2017
-- Expanded Vifor Pharma partnership now totals $155 million in upfront cash commitments, $1.2 billion in potential milestone payments, plus substantial royalties on potential net sales -- -- Initiated Phase III clinical trial of Avacopan for the treatment of ANCA Vasculitis -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN V...
Mar 1, 2017
MOUNTAIN VIEW, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's fourth quarter 2016 financial results will be released after market close on Tuesday, March 14, 2017. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on March 14, 2017 to...
Feb 28, 2017
MOUNTAIN VIEW, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 10:00 a.m. ET. The conference will be held at the Boston Marriott Cop...
Feb 14, 2017
-- ChemoCentryx retains all rights in the United States and China; Vifor Pharma gains additional marketing rights in Asia, including Japan and Middle Eastern markets -- ...
Jan 20, 2017
MOUNTAIN VIEW, Calif., Jan. 20, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI) today announced the presentation of results from its immuno-oncology program at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium being held January 19-21, 2017 in San Francisco, California. The presentation highl...
Jan 9, 2017
-- Company Initiates Phase III "ADVOCATE" Clinical Trial for Complement Receptor Inhibitor Avacopan in ANCA Vasculitis; Development Path Outlined in Rare Kidney Disease for Chemokine Receptor Inhibitor ‘CCX140' -- MOUNTAIN VIEW, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today provided a corporate upda...
Jan 4, 2017
MOUNTAIN VIEW, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 12:00 p.m. PT. The conference will be held at the Westin St. Francis Ho...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase